Innovus Pharmaceuticals (OTCMKTS:INNVD) vs. Can-Fite BioPharma (NYSE:CANF) Head-To-Head Comparison

Can-Fite BioPharma (NYSE:CANF) and Innovus Pharmaceuticals (OTCMKTS:INNVD) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends and earnings.

Profitability

This table compares Can-Fite BioPharma and Innovus Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Can-Fite BioPharma	N/A	N/A	N/A
Innovus Pharmaceuticals	-34.51%	-682.54%	-78.57%

Valuation and Earnings

This table compares Can-Fite BioPharma and Innovus Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Can-Fite BioPharma	$560,000.00	10.26	-$7.63 million	($35.80)	-0.12
Innovus Pharmaceuticals	$23.99 million	0.00	-$8.28 million	($4.16)	N/A

Can-Fite BioPharma has higher earnings, but lower revenue than Innovus Pharmaceuticals. Can-Fite BioPharma is trading at a lower price-to-earnings ratio than Innovus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Can-Fite BioPharma and Innovus Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Can-Fite BioPharma	0	2	1	0	2.33
Innovus Pharmaceuticals	0	0	0	0	0.00

Can-Fite BioPharma presently has a consensus target price of $65.00, indicating a potential upside of 1,380.64%. Given Can-Fite BioPharma’s stronger consensus rating and higher probable upside, analysts plainly believe Can-Fite BioPharma is more favorable than Innovus Pharmaceuticals.

Institutional & Insider Ownership

21.0% of Can-Fite BioPharma shares are owned by institutional investors. Comparatively, 10.4% of Innovus Pharmaceuticals shares are owned by institutional investors. 0.8% of Can-Fite BioPharma shares are owned by insiders. Comparatively, 16.4% of Innovus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Volatility & Risk

Can-Fite BioPharma has a beta of 1.07, meaning that its share price is 7% more volatile than the S&P 500. Comparatively, Innovus Pharmaceuticals has a beta of 2.89, meaning that its share price is 189% more volatile than the S&P 500.

Summary

Can-Fite BioPharma beats Innovus Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.

About Innovus Pharmaceuticals

Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the development, licensing, and commercialization of non-prescription medicines and consumer care products in the United States. Its products include Zestra, a proprietary blend of essential oils to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph compliant benzocaine gel for premature ejaculation; Sensum+, a non-medicated cream for penile sensitivity; Zestra Glide, a water-based longer lasting lubricant; Vesele, a proprietary oral supplement for promoting sexual health; and Androferti, a natural supplement to support male reproductive health and sperm quality. The company also offers Beyond Human testosterone booster, ketones, krill oil, omega 3 fish oil, Vision Formula, blood sugar, colon cleanse, green coffee extract, and growth agent; RecalMax for brain health; UriVarx, a supplement for overactive bladder and urinary incontinence; PEVarx, a supplement for peak sexual performance; ProstaGorx, a supplement for prostate support; and FlutiCare, a nasal spray. In addition, its products include Apeaz for pain relief; AllerVarx for allergy relief; ArthriVarx for joint pain; Xyralid, a hemorrhoid cream; Can-C eye drop and eye care capsule; MZS, a melatonin formula to enhance sleep patterns; and Diabasens, a diabetic foot cream. The company's pipeline products comprise UriVarx for urinary tract infection; Xyralid suppositories for hemorrhoidal symptoms; GlucoGorx supplement, glucometer, lancing device, and GlucoGorx strip for blood sugar levels; Vesele and RecalMax nitric oxide strips. It markets and sells its products through commercial partners to primary care physicians, urologists, gynecologists, and therapists, as well as to other healthcare providers; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.